{"id":"phenazone","rwe":[{"pmid":"41837436","year":"2026","title":"Quality by Design-Based Stability-Indicating RP-HPLC Method for Diminazene Diaceturate in Veterinary Formulation Supported by LC-MS Characterization of Degradation Products.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"41689661","year":"2026","title":"Comprehensive pollutant screening in honey using integrated targeted and non-targeted LC-Q-Orbitrap HRMS.","finding":"","journal":"Analytical and bioanalytical chemistry","studyType":"Clinical Study"},{"pmid":"40780996","year":"2026","title":"Anaphylactic shock induced by HEC® ointment: A CARE case report.","finding":"","journal":"European annals of otorhinolaryngology, head and neck diseases","studyType":"Clinical Study"},{"pmid":"40649329","year":"2025","title":"Polymorphism and Phase-Transition Thermodynamic Properties of Phenazone (Antipyrine).","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"30000532","year":"2006","title":"Antipyrine.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"phenazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Nicotinate phosphoribosyltransferase","category":"target"},{"label":"NAPRT","category":"gene"},{"label":"TRPA1","category":"gene"},{"label":"N02BB01","category":"atc"},{"label":"Auricular (Otic)","category":"route"},{"label":"Liquid","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"Infective otitis media","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Acute cerebrovascular insufficiency","Acute nephropathy","Alcoholism","Angle-closure glaucoma","Arterial aneurysm","Arteriosclerotic vascular disease","Benign prostatic hyperplasia","Conduction disorder of the heart","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Glaucoma","Heart disease","Hepatic failure","Hypertensive disorder","Hyperthyroidism","Organic Cardiac Disease","Perforation of tympanic membrane","Peripheral vascular disease","Poisoning by acetaminophen","Porphyria"],"specialPopulations":{"Pregnancy":"Category C. Animal reproduction studies have not been conducted with Antipyrine and Benzocaine Otic Solution. It is also not known whether Antipyrine and Benzocaine Otic Solution can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Antipyrine and Benzocaine Otic Solution should be given to pregnant woman only if clearly needed."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=phenazone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:56:30.453266+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:56:46.320926+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:56:35.824428+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=phenazone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:56:36.211820+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1526434/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:56:36.911819+00:00"}},"allNames":"azophen","offLabel":[],"synonyms":["phenazone","analgesin","analgesine","anodynine","antipyrin","azophen","azophene","dimethyloxychinizin","dimethyloxyquinazine","fenazone","methozin","oxydimethylquinazine","phenazon","pyrazophyl","phenylone","antipyrine"],"timeline":[{"date":"1964-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Phenazone (Azophen) is a marketed drug primarily indicated for the treatment of infective otitis media, with a key composition patent expiring in 2028. Its mechanism of action, inhibiting nicotinate phosphoribosyltransferase, sets it apart in the market. The primary risk is competition from same-class drugs like metamizole, which may limit its market share.","approvals":[{"date":"1964-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Azophen","ecosystem":[{"indication":"Infective otitis media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Nicotinate phosphoribosyltransferase","targets":[{"gene":"NAPRT","source":"DrugCentral","target":"Nicotinate phosphoribosyltransferase","protein":"Nicotinate phosphoribosyltransferase"},{"gene":"TRPA1","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily A member 1","protein":"Transient receptor potential cation channel subfamily A member 1"}],"modality":"Small Molecule","drugClass":"phenazone","explanation":"","oneSentence":"","technicalDetail":"Azophen (phenazone) acts as a competitive inhibitor of nicotinate phosphoribosyltransferase, thereby reducing the conversion of nicotinate to NAD+, which is crucial for bacterial growth and replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/861","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=phenazone","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=phenazone","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:18:35.578810","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:56:46.321053+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metamizole","drugSlug":"metamizole","fdaApproval":"","relationship":"same-class"}],"genericName":"phenazone","indications":{"approved":[{"name":"Infective otitis media","source":"DrugCentral","snomedId":312218008,"regulator":"FDA"}],"offLabel":[{"name":"Impacted cerumen","source":"DrugCentral","drugName":"phenazone"},{"name":"Migraine","source":"DrugCentral","drugName":"phenazone"},{"name":"Otalgia","source":"DrugCentral","drugName":"phenazone","evidenceCount":9,"evidenceLevel":"emerging"},{"name":"Tension-type headache","source":"DrugCentral","drugName":"phenazone","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Vascular headache","source":"DrugCentral","drugName":"phenazone","evidenceCount":2,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metamizole","brandName":"metamizole","genericName":"metamizole","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":["Healthy Adult Subjects"],"enrollment":27,"completionDate":"2018-10-23"},{"nctId":"NCT03289234","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11-16","conditions":["Hepatic Impairment","Healthy"],"enrollment":22,"completionDate":"2018-07-24"},{"nctId":"NCT03289208","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-10-27","conditions":["Renal Impairment","Healthy"],"enrollment":30,"completionDate":"2018-04-20"},{"nctId":"NCT03664544","phase":"PHASE1","title":"PK Study in Subjects With Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-11-06","conditions":["Severe Hepatic Impairment","Healthy"],"enrollment":12,"completionDate":"2019-03-25"},{"nctId":"NCT00821821","phase":"PHASE2","title":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-02","conditions":["Acute Ischemic Stroke (AIS)"],"enrollment":36,"completionDate":"2010-11"},{"nctId":"NCT03346538","phase":"PHASE2","title":"Dose Finding Study of MCI-186 in Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-11-17","conditions":["Acute Ischemic Stroke"],"enrollment":17,"completionDate":"2018-05-14"},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":["Healthy Adult Subjects"],"enrollment":84,"completionDate":"2019-01-08"},{"nctId":"NCT04776135","phase":"PHASE1","title":"Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2021-02-26","conditions":["Healthy Adult Subjects"],"enrollment":36,"completionDate":"2021-04-16"},{"nctId":"NCT05342597","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-06-10","conditions":["Healthy Adult Subjects"],"enrollment":16,"completionDate":"2019-07-24"},{"nctId":"NCT04176224","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-17","conditions":["Japanese Patients With ALS"],"enrollment":9,"completionDate":"2019-09-04"},{"nctId":"NCT04493281","phase":"PHASE1","title":"Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-03-22","conditions":["Healthy Adult Subjects"],"enrollment":42,"completionDate":"2019-05-09"},{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":["Cerebral Infarction"],"enrollment":401,"completionDate":"2006-10"},{"nctId":"NCT04254913","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2020-01-24","conditions":["Japanese Patients With ALS"],"enrollment":6,"completionDate":"2020-04-22"},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":["Healthy Adult Subjects"],"enrollment":74,"completionDate":"2018-08-03"},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":25,"completionDate":"2008-07"},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":181,"completionDate":"2009-05"},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":206,"completionDate":"2008-09"},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":137,"completionDate":"2014-10"},{"nctId":"NCT04165824","phase":"PHASE3","title":"Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-11-18","conditions":["ALS"],"enrollment":185,"completionDate":"2021-10-07"},{"nctId":"NCT04577404","phase":"PHASE3","title":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-10-29","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":124,"completionDate":"2023-08-09"},{"nctId":"NCT05568615","phase":"PHASE3","title":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2022-10-26","conditions":["ALS"],"enrollment":15,"completionDate":"2023-06-27"},{"nctId":"NCT04569084","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-11-13","conditions":["ALS"],"enrollment":384,"completionDate":"2023-09-29"},{"nctId":"NCT05151471","phase":"PHASE3","title":"Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2022-01-11","conditions":["ALS"],"enrollment":202,"completionDate":"2023-09-29"},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":["Ischemic Stroke"],"enrollment":300,"completionDate":"2027-07-31"},{"nctId":"NCT05323812","phase":"PHASE2","title":"ASURE: Alzheimer Study Using oRal Edaravone","status":"COMPLETED","sponsor":"Treeway B.V.","startDate":"2023-03-01","conditions":["Alzheimer Disease"],"enrollment":61,"completionDate":"2024-12-30"},{"nctId":"NCT05540262","phase":"NA","title":"Edaravone in the Treatment of Optic Neuritis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-01-15","conditions":["Optic Neuritis"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":["Healthy Adult Subjects"],"enrollment":72,"completionDate":"2021-01-08"},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":["Healthy Adult Subjects"],"enrollment":29,"completionDate":"2023-12-14"},{"nctId":"NCT02037893","phase":"PHASE2","title":"Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2013-11","conditions":["Acute Otitis Media"],"enrollment":112,"completionDate":"2014-09"},{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":["Acute Ischemic Stroke"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT04259255","phase":"","title":"Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)","status":"UNKNOWN","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-10-21","conditions":["Amyotrophic Lateral Sclerosis","ALS"],"enrollment":300,"completionDate":"2024-03"},{"nctId":"NCT02153541","phase":"PHASE2","title":"Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults","status":"UNKNOWN","sponsor":"Global United Pharmaceutical Corporation","startDate":"2023-04-01","conditions":["Asthma"],"enrollment":50,"completionDate":"2023-08-01"},{"nctId":"NCT05024526","phase":"NA","title":"Protective Effects of Edaravone Dexborneol","status":"UNKNOWN","sponsor":"Lili Cao","startDate":"2021-04-01","conditions":["Acute Ischemic Stroke"],"enrollment":80,"completionDate":"2023-03-31"},{"nctId":"NCT04218513","phase":"PHASE1","title":"Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-05-10","conditions":["Drug-drug Interaction"],"enrollment":24,"completionDate":"2019-05-31"},{"nctId":"NCT03968042","phase":"PHASE2","title":"Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-06-30","conditions":["Alcohol-induced Brain Injury"],"enrollment":150,"completionDate":"2021-12"},{"nctId":"NCT04391361","phase":"PHASE2","title":"The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-11-01","conditions":["Amyotrophic Lateral Sclerosis","Respiratory Function","Scopolamine"],"enrollment":30,"completionDate":"2023-10-31"},{"nctId":"NCT03272802","phase":"PHASE2,PHASE3","title":"Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-03-16","conditions":["Neuromuscular Diseases"],"enrollment":20,"completionDate":"2019-09-16"},{"nctId":"NCT02430350","phase":"PHASE3","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":["Acute Ischemic Stroke"],"enrollment":1200,"completionDate":"2016-12"},{"nctId":"NCT02644915","phase":"NA","title":"Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-03","conditions":["Kidney Transplantation"],"enrollment":150,"completionDate":"2016-10"},{"nctId":"NCT02616458","phase":"NA","title":"The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":["Otitis Media"],"enrollment":310,"completionDate":"2015-08"},{"nctId":"NCT01929096","phase":"PHASE2","title":"Compound Edaravone Injection for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":["Acute Ischemic Stroke"],"enrollment":400,"completionDate":"2015-02"},{"nctId":"NCT00265239","phase":"PHASE4","title":"Pilot Study of Edaravone to Treat Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2001-04","conditions":["Myocardial Infarction","Reperfusion Injury"],"enrollment":104,"completionDate":"2007-06"},{"nctId":"NCT01894334","phase":"NA","title":"Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-04","conditions":["Acute Aortic Dissection"],"enrollment":220,"completionDate":"2015-01"},{"nctId":"NCT01865201","phase":"PHASE2","title":"Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2009-03","conditions":["Nasopharyngeal Carcinoma","Brain Necrosis"],"enrollment":154,"completionDate":"2012-09"},{"nctId":"NCT01584271","phase":"PHASE2","title":"Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)","status":"UNKNOWN","sponsor":"Assuta Hospital Systems","startDate":"2011-07","conditions":["Acute Otitis Externa"],"enrollment":75,"completionDate":"2013-12"},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":["Stroke"],"enrollment":40,"completionDate":"2013-12"},{"nctId":"NCT00153946","phase":"PHASE4","title":"Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Combination Therapy for Acute Ischemic Stroke Study Group","startDate":"2004-08","conditions":["Stroke"],"enrollment":814,"completionDate":"2008-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Auricular (Otic)","formulation":"Liquid, Solution","formulations":[{"form":"LIQUID","route":"AURICULAR (OTIC)","productName":"OrtizolOtic Solution"},{"form":"SOLUTION","route":"AURICULAR (OTIC)","productName":"Antipyrine and Benzocaine"}]},"crossReferences":{"NUI":"N0000146454","MMSL":"4210","NDDF":"001607","UNII":"T3CHA1B51H","VUID":"4018116","CHEBI":"CHEBI:31225","VANDF":"4018116","INN_ID":"413","RXNORM":"1001","UMLSCUI":"C0003420","chemblId":"CHEMBL1526434","ChEMBL_ID":"CHEMBL277474","KEGG_DRUG":"D01776","DRUGBANK_ID":"DB01435","PUBCHEM_CID":"2206","SNOMEDCT_US":"412090007","MESH_DESCRIPTOR_UI":"D000983","MESH_SUPPLEMENTAL_RECORD_UI":"C027436"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"12.0 hours","clearance":"0.64 mL/min/kg","bioavailability":"99%","fractionUnbound":"0.93%","volumeOfDistribution":"0.77 L/kg"},"publicationCount":362,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"N02BB01","allCodes":["N02BB01","N02BB51","N02BB71","S02DA03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 May","pmid":"41837436","title":"Quality by Design-Based Stability-Indicating RP-HPLC Method for Diminazene Diaceturate in Veterinary Formulation Supported by LC-MS Characterization of Degradation Products.","journal":"Biomedical chromatography : BMC"},{"date":"2026 Feb 14","pmid":"41689661","title":"Comprehensive pollutant screening in honey using integrated targeted and non-targeted LC-Q-Orbitrap HRMS.","journal":"Analytical and bioanalytical chemistry"},{"date":"2026 Jan","pmid":"40780996","title":"Anaphylactic shock induced by HEC® ointment: A CARE case report.","journal":"European annals of otorhinolaryngology, head and neck diseases"},{"date":"2025 Jun 30","pmid":"40649329","title":"Polymorphism and Phase-Transition Thermodynamic Properties of Phenazone (Antipyrine).","journal":"Molecules (Basel, Switzerland)"},{"date":"2006","pmid":"30000532","title":"Antipyrine.","journal":""}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1964-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:56:46.321053+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}